The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.

Method for enhancing the bioavailability of orally administered benzoic acid in an animal includes orally administering to the animal an animal feed which comprises benzoic acid prills having neither edges nor spikes, wherein the benzoic acid prills exhibit a rate and/or extent of in vitro dissolution of benzoic acid in a physiologically relevant dissolution fluid which is higher when compared to nonspherical benzoic acid flakes.

This document provides dietary supplement compositions. For example, this document provides dietary supplement compositions that include a Ganoderma lucidum extract.

A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, ethylenediaminedisuccinic acid, an oxidant, water, and optionally citric acid, is provided along with temperature conditions to directly form within the reaction mixture, a stable dispersion of cerium oxide nanoparticles. Biocompatible nanoparticles comprised of cerium oxide, ethylenediaminedisuccinic acid, and optionally citric acid, are described. An increase in catalase-like enzyme activity is demonstrated by cerium oxide nanoparticles prepared with citric acid and ethylenediaminedisuccinic acid.

Systems, methods, and materials are described for making solid unit dosage forms for administration of therapeutic and biotherapeutic agents, particularly dosage forms for various enteral, nasal, pulmonary, vaginal, topical, and other suitable non-injection delivery routes. Contact freezing methods may be used in conjunction with lyophilization or vacuum drying to process a liquid formulation and produce solid unit dosage forms having a high degree of structural stability while preserving the therapeutic activity of the included agents.

The present invention discloses a spray drying process characterized by continuous preparation and immediate spray drying of a solution comprising at least one active pharmaceutical ingredient and/or at least one excipient, and at least one solvent. The said active pharmaceutical ingredient(s) and solvent(s) are combined, alone or along with one or more excipients to form a first suspension. Said suspension is continuously fed to an intensifier pump that pushes said suspension through at least one micro-reaction chamber and/or at least one micro-channel where the suspension's solid(s) component(s) is(are) dissolved into said solvent(s) by means of high energy mixing I forced contact at micro, nano and molecular level to form a solution stream. The said solution stream is then immediately and continuously fed to the spray dryer through at least one atomization nozzle, drying said atomized stream to obtain solid particles and collecting said solid particles. Single component particles or multi-component particles, particulate amorphous solid dispersion and pharmaceutical compositions are also disclosed. The present invention also discloses amorphous solid dispersions obtained by the method of the invention as well as pharmaceutical compositions containing the same.

A cannabis powder composition and method of manufacture which is a non-extracted botanical ingredient that is manufactured to preserve the natural levels of beneficial elements found in the cannabis plant including cannabinoids, terpenes, flavonoids, essential vitamins, fatty acids, protein and fiber. The cannabis powder is produced using a low heat technology which controls decarboxylation and allows the product to remain in an active and highly bioavailable state

A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.

Kava and kratom compositions are described herein along with the methods of producing the same. The description contained herein describes methods for making a purified kava composition that is free or substantially free of flavokavain A and flavokavain B. In some embodiments, the kava composition is formulated as a ready-to-drink beverage. Certain compositions comprise a combination of a kava composition and a kratom composition made in accordance with the methods described herein.

A method for a pimavanserin solid preparation. The method improves the fluidity of pimavanserin powder during preparation, can improve the stability of the content of an active ingredient in the solid preparation, and has the characteristics of rapid dissolution and release and good compression moldability.